EP1210939B1 - Pharmazeutische Zusammensetzungen, die Paracetamol und L-Cystein oder eine Vorstufe davon enthalten - Google Patents

Pharmazeutische Zusammensetzungen, die Paracetamol und L-Cystein oder eine Vorstufe davon enthalten Download PDF

Info

Publication number
EP1210939B1
EP1210939B1 EP02002974A EP02002974A EP1210939B1 EP 1210939 B1 EP1210939 B1 EP 1210939B1 EP 02002974 A EP02002974 A EP 02002974A EP 02002974 A EP02002974 A EP 02002974A EP 1210939 B1 EP1210939 B1 EP 1210939B1
Authority
EP
European Patent Office
Prior art keywords
hydroxyacetanilide
cysteine
mixture
composition
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP02002974A
Other languages
English (en)
French (fr)
Other versions
EP1210939A3 (de
EP1210939A2 (de
Inventor
Roger Spencer Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinclair Pharmaceuticals Ltd
Original Assignee
Sinclair Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinclair Pharmaceuticals Ltd filed Critical Sinclair Pharmaceuticals Ltd
Publication of EP1210939A2 publication Critical patent/EP1210939A2/de
Publication of EP1210939A3 publication Critical patent/EP1210939A3/de
Application granted granted Critical
Publication of EP1210939B1 publication Critical patent/EP1210939B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • This invention relates to analgesics and in particular to formulations of p-hydroxyacetanilide.
  • p-Hydroxyacetanilide or paracetamol finds wide use as an analgesic and has the particular advantage of having a relatively pure analgesic action with few side effects when used in normal dosages.
  • overdoses of the drug can be very toxic and the ready availability of the drug has led to its use on a quite significant scale as a means of attempting suicide. Even when the overdose is not fatal it can lead to severe liver injury and the methods at present available for the treatment of an overdose of the drug are often ineffective in preventing this.
  • Formulation of p-hydroxyacetanilide together with L-cysteine or a compound which is converted thereto in vivo has the very great advantage that an overdose of the drug automatically results in an increase in the amount of glutathione synthesised by the body thus countering the toxic effect of the overdose.
  • the glutathione precursor may also detoxify the p-hydroxyacetanilide by providing intracellular sulphate, the formation of its sulphate being an alternative safe metabolic pathway for the disposal of p-hydroxyacetanilide.
  • shaped is used herein in its normal sense of having a defined form as, for example, in a tablet, and “shaping" is used to indicate the production of such a defined form.
  • the final composition obtained by such techniques may not necessarily contain a significant amount of water but the defect of these prior art processes is that their initial stages involve a wet process, the production of the marketed product Pameton also involving such a process. Without limitation to any particular mode of operation, it is believed that one advantage of the present invention over the prior art lies in the avoidance of hydrolysis of the L-cysteine or its precursor with the formation of volatile sulphur-containing products.
  • a solid pharmaceutical composition comprising p-hydroxyacetanilide and DL-methionine or like compound through shaping a solid mixture which is produced through admixture of the components in the solid state and that the composition, although not odourless, has a more acceptable odour than that of a composition derived from a granular product obtained by a wet process.
  • the product produced by the dry process of the present invention has the further advantage of containing a high amount of p-hydroxyacetanilide per unit volume so that the size of a tablet containing a unit dosage of 500 mg p-hydroxyacetanilide is readily acceptable to the patient.
  • the present invention thus includes a solid ungranulated particulate mixture as described in claim 8.
  • L-cysteine or its precursor rather than that of the p-hydroxyacetanilide which is most relevant to an improvement of the prior art procedures for the formulation of the pharmaceutical composition.
  • the ease of producing a pharmaceutical composition according to the invention is enhanced through the use of L-cysteine or its precursor in a form substantially of a particle size which is less than 1,000 microns and conveniently less than the standard sieve size of 710 microns.
  • substantially of a particle size it is meant that a proportion by weight of at least 80 percent is of the size indicated, although preferably at least 90 percent and conveniently essentially 100 percent may be of the size indicated.
  • the requirement as to a minimum particle size is less critical. However, conveniently less than 50 percent by weight and particularly less than 30 percent by weight of the L-cysteine or its precursor is of a particle size less than 250 microns.
  • a proportion of the L-cysteine or its precursor of at least 50% by weight, conveniently of at least 60% by weight and particularly of at least 70% by weight, is of a particle size in the range of 250 to 1,000 microns and conveniently of 250 to 710 microns.
  • the size of the p-hydroxyacetanilide component of the mixture is of less significance and a commercially available sample may be suitable for direct use.
  • the particle size of such a sample may, for example, be such that a proportion of 50 to 60 percent by weight has a particle size of between 53 and 150 microns.
  • the material may be subjected to a simple screening procedure before use to ensure that it is substantially of a particle size less than a particular amount, for example 1,000 or particularly 710 microns.
  • the phrase "substantially of a particle size" has the same meaning as previously and the same further preferences apply, i.e. preferably at least 90 percent by weight and conveniently essentially 100 percent by weight being of the size indicated.
  • the amount of water in the composition is no more than 2.5 or 2.0 percent by weight of the whole, preferably no more than 1.5 or 1.0 percent and conveniently no more than 0.8 percent.
  • the composition therefore preferably consists of essentially dry materials, the presence of some water is desirable for effective binding, so that the composition preferably includes an amount of water which is at least 0.4 percent by weight of the whole, preferably at least 0.5 percent and conveniently at least 0.6 percent.
  • the proportion by weight of water present in a pharmaceutical composition produced by the process of the present invention is thus preferably in a range from 0.4 or 0.5 to 2.5 percent by weight of the whole, with further preferences as to the upper and lower limits being as previously indicated, a particularly preferred range being from 0.5 to 1.0 percent, conveniently from 0.6 to 0.8 percent, for example 0.7 percent.
  • the amount of water present prior to the shaping of the composition will generally conform to the figures indicated for the composition as there is usually no significant change in water content involved in the process of shaping the mixture of compounds.
  • the figures quoted for water content herein are those obtained by measurement using the Karl Fischer technique. This involves the use of a solution of iodine and sulphur dioxide in pyridine/methanol to titrate water.
  • the reagent is commercially available.
  • L-cysteine-providing component of the pharmaceutical composition either L-cysteine or any compound which is metabolised by the body to provide L-cysteine may be used. It will be appreciated that the compound need not necessarily all be converted to L-cysteine nor need all the L-cysteine be converted into glutathione. The function of this component is, in the event of an overdose of the drug being taken and the normal supply of glutathione in the body being exhausted, to provide a replacement source of L-cysteine.
  • L-cystine In addition to l-cysteine itself, the naturally occurring amino acids of particular interest are L-cystine and particularly L-methionine, L-methionine being preferred to L-cysteine itself.
  • the DL isomer of the sulphur-containing amino acids can also be used and in the case of methionine but not of cysteine both the D and L isomers provide a source of the L-cysteine component of glutathione.
  • a 0 isomer may also contribute by the provision of intracellular sulphate.
  • An L isomer and in particular L-methionine does have the advantage of greater purity and possibly of being available in a form having a particle size range which is acceptable for immediate use thereby avoiding the necessity of milling.
  • L-cysteine a particularly suitable type of dipeptide being one which provides two of the amino acid units of glutathione, i.e. L-glutamyl-L-cysteine or L-cysteinyl-glycine.
  • L-cysteine or another amino acid is used.
  • the L-cysteine-providing component may if desired be in the form of a salt with any physiologically acceptable acid or base.
  • salts may be formed with various suitable inorganic and organic acids.
  • inorganic acids are phosphonic acid, nitric acid, sulphuric acid and particularly the hydrohalic acids hydrochloric acid, hydrobromic acid and hydroiodic acid.
  • organic acids are citric acid, oxalic acid, fumaric acid, maleic acid, lactic acid, succinic acid, malic acid, tartaric acid and methane sulphonic acid.
  • salts may be formed with various suitable inorganic and organic bases. Examples of these are the alkali metal hydroxides, for example sodium hydroxide, quaternary ammonium hydroxides and amines such as tris (tris representing 2-amino-2-hydroxymethyl propane 1,3-diol).
  • the major consideration is the provision of a sufficient supply of glutathione to counter toxicity in the event of an overdose of p-hydroxyacetanilide depleting the normal supply of glutathione.
  • the proportion of this compound by weight relative to the p-hydroxyacetanilide will of course vary depending particularly upon the nature of the compound used but an amount in the range from 10 to 50%, and preferably 15 to 25%, for example 20%, is usually suitable.
  • the composition may, if desired, contain other active ingredients, for example one or more of the compounds caffeine, caffeine hydrate, codeine, codeine phosphate, dihydrocodeine tartrate, pseudoephidrine hydrochloride and phenolphthaline. Of these compounds codeine and/or caffeine in one form of another are most usually formulated together with p-hydroxyacetanilide. It will be appreciated, however, that the present formulation will not counter any toxic effects arising from overdoses of these other ingredients. However, these effects may not be as severe as those arising from the p-hydroxyacetanilide and compositions additionally containing codeine or a salt thereof are of particular interest.
  • a pharmaceutical composition produced according to the present invention will usually contain a physiologically acceptable solid carrier.
  • the present invention thus includes a shaped pharmaceutical composition
  • a shaped pharmaceutical composition comprising a non-granular solid mixture comprising p-hydroxyacetanilide and L-cysteine or a compound which is convertible thereto in vivo together with a physiologically acceptable solid carrier.
  • the present invention further, includes a directly compressed pharmaceutical composition as described in claim 10.
  • a carrier material used in a pharmaceutical composition according to the present invention may be conventional to the art of pharmaceutical formulation but such materials are preferably selected in both nature and quantity with a view to producing particular physical properties for the composition.
  • the composition may conveniently contain one or more of a component which acts as a lubricant for flow of the various components together, a component which enhances adhesion of the components of the composition during shaping, and a component which aids dispersion of the composition in the body.
  • the presence of an adhesive agent is of especial interst.
  • a lubricant is a starch product such as sodium starch glycollate, for example Explotab;
  • an adhesive agent is a vinyl polymer, particularly an N-vinyl polymer such as polyvinylpyrrolidone, together with a cellulose product such as microcrystalline cellulose, for example Avicel PH102, which not only aids adhesion through conferring mechanical strength but which also exerts a wicking effect thereby aiding the action of the dispersing agent; and as a dispersing agent is magnesium stearate.
  • These components may be present in conventional proportions, for example an amount by weight of the whole composition equal to 0.5 to 2 percent of sodium starch glycollate, for example 0.96 percent, 2 to 8 percent of polyvinylpyrrolidone, for example 4.08 percent, 0.15 to 0.6 percent of cellulose, for example 0.32 percent, and 0.7 to 3 percent of magnesium stearate, for example 1.44 percent, or a similar amount of an alternative to these materials performing a similar function.
  • the process of the present invention involves admixture of the various components, conveniently in an order commencing with the active ingredients followed by the carrier materials.
  • the p-hydroxyacetanilide mixed with the L-cysteine or its precursor may conveniently be in a form in which it is already coated with the primary adhesive agent such as polyvinylpyrrolidone (p-hydroxyacetanilide being commercially available in such a coated form).
  • L-cysteine or its precursor in a physical form with a particular particle size
  • the carrier materials like the p-hydroxyacetanilide, may often be used in the physical form as supplied in the usual commercial samples of the material or alternatively may be subjected to a simple screening procedure to remove particles above 1,000 or particularly 710 microns. It will often be the case therefore that the whole mixture including the p-hydroxyacetanilide and the carrier materials conforms to the main preference indicated for the L-cysteine or its precursor so that it is substantially of a particle size which is less than 1,000 microns and conveniently less than 710 microns.
  • the mixture is shaped or formed, particularly by compression using a suitable level of pressure.
  • a conventional compression machine may be used and this will usually effect a degree of compression which produces a level of hardness in the range of about 5 to 12 kilopascals, for example 5 to 7 kilopascals.
  • the shaped product will generally have the form of a tablet, conveniently with either an essentially circular cross section or an elliptical cross section with a length greater than its width.
  • the product may be treated further as desired, for example to provide a coating which will assist in preventing the take up of moisture during storage.
  • Such a coating may consist of wax or alternatively of a film forming polymer such as an acrylic polymer, for example the aminoalkyl methacrylate copolymer marketed under the trade name EUDRAGIT E100.
  • compositions may conveniently be formulated in unit dosage form, i.e. in the form of discrete portions each containing a unit dose, or a multiple or sub-multiple of a unit dose, of p-hydroxyacetanilide.
  • the recommended daily dose of p-hydroxyacetanilide for an adult human patient is of the order of from about 1.5 to about 4 grams daily, as required, usually being divided into 3 or 4 spaced doses of from about 0.5 to about 1 gram and with the dose being approximately halved for children.
  • individual tablets contain from 0.1 to about 2 grams, preferably from about 0.25 to about 0.75 or 1 gram and usually 0.5 grams.
  • Veterinary doses are on a similar mg/kg basis but the present invention is of particular application to the production of pharmaceutical compositions for human use.
  • p-Hydroxyacetanilide is of value for use not only as an analgesic but also in other contexts, particularly as an antipyretic.
  • the present invention thus includes the use of a non-granular, solid mixture comprising p-hydroxyacetanilide and L-cysteine or a compound which is converted thereto in vivo in which the L-cysteine or its precursor is substantially of a particle size less than 1,000 microns and is of 10 to 50% by weight of the amount of p-hydroxyacetanilide, for the manufacture of a medicament for use as an analgesic or antipyretic.
  • Also included by the present invention is a method for the treatment of a patient in need thereof, for example a patient requiring analgesic or antipyretic treatment, with a therapeutically effective amount of a pharmaceutical composition as described herein.
  • the present invention further includes any new process for the production of a pharmaceutical composition comprising p-hydrodyacetanilide and L-cysteine or a compound which is converted thereto in vivo , and also any such new a pharmaceutical composition; as is described hereinbefore.
  • Example 1 Production of Composition of p-Hydroxyacetanilide and DL-Methionine
  • OL-Methionine was milled before use using either a Fitzmill or a dispersion mill in order to reduce the particle size of the commercial sample. Analysis of a typical milled sample shows the following distribution by weight on passing the material through a succession of standard sieves of decreasing size:
  • p-Hydroxyacetanilide was treated with a solution of polyvinylpyrrolidone and dried in a fluid bed drier. (Such a coated material is commercially available.) The coated material was passed through a 710 micron sieve.
  • the DL-methionine (1556.49 g) was transferred into a 20 kg drum which had been cleaned and dried and the polyvinylpyrrolidone-treated p-hydroxyacetanilide (paracetamol, sieved D.C. grade, 95% p-hydroxyacetanilide and 5% polyvinylpyrrolidone by weight) (8171.60 g) was added to the drum.
  • the drum was placed on an adapted Winkworth Turbula Blender and blending carried out for 10 minutes at 44 rpm.
  • Magnesium stearate (158.54 g) was passed through a 710 micron mesh sieve and 144.13 g of the sieved material was added to a clean double-lined polythene bag.
  • To the bag was then added approximately double the weight (288.26 g) of the blend of p-hydroxyacetanilide, methionine, sodium starch glycollate and microcrystalline cellulose from the Blender, the whole then being manually mixed in the bag for 3 minutes.
  • the mixture from the bag was then added to the remainder of the blend of the other components in the Blender and the whole blended for 5 minutes at 44 rpm.
  • the bulk powder blend was transferred into double-lined polythene bags which were in turn placed, prior to tabletting, in lidded white polycarbonate pots laden with an ample supply of dessicant sachets.
  • the powder was compressed into tablets in amounts of approximately 10,000 g using a Manesty-03-8 compression machine providing a hardness of 5 to 7 kilopascals.
  • the target mass per tablet was 642.47 mg with the individual mass being within the ⁇ 5% target range of 611-674 mg. These tablets were placed in a coating pan which was then rotated.
  • Example 1 The procedure of Example 1 was repeated exactly but replacing the 1556.49 g of DL-methionine by the same weight of L-methionine which did not, however, require milling before use. .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (18)

  1. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, umfassend p-Hydroxyacetanilid und L-Cystein oder eine Verbindung, die dazu in vivo umgewandelt wird, wobei das Verfahren das Mischen von p-Hydroxyacetanilid und L-Cystein oder dessen Vorstufe zusammen mit einem Bindemittel und einem Gleitmittel im festen Zustand und dann das Umwandeln des Feststoffgemischs in ein geformtes Produkt umfasst,
    dadurch gekennzeichnet, dass
    (i) das Mischen und Umwandeln in ein geformtes Produkt keinen Nassverabeitungsschritt einschließt,
    (ii) das L-Cystein oder dessen Vorstufe im wesentlichen eine Partikelgröße von weniger als 1000 µm aufweist und mit 10 bis 50 Gew.-%, bezogen auf die Menge des p-Hydroxyacetanilids, vorliegt,
    (iii) das Formen durch direkte Komprimierung erfolgt mit der Maßgabe, dass beim Schritt des Mischens das p-Hydroxyacetanilid nicht in einer mit Polyvinylpyrrolidon beschichteten Form, in welcher das Polyvinylpyrrolidon mit 2 bis 8 Gew.-% der Zusammensetzung vorliegt, eingesetzt wird.
  2. Verfahren nach Anspruch 1, wobei das Feststoffgemisch nicht-granulär ist.
  3. Verfahren nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass das Bindemittel Polyvinylpyrrolidon ist.
  4. Verfahren nach Anspruch 3, dadurch gekennzeichnet, dass das Gleitmittel Natriumstärkeglycolat ist.
  5. Verfahren nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, dass die Menge an Wasser im Feststoffgemisch im Bereich von 0,5 bis 2,5 Gew.-% des Gesamtfeststoffgemischs liegt.
  6. Verfahren nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass die Zusammensetzung p-Hydroxyacetanilid und DL-Methionin oder ein physiologisch verträgliches Salz davon umfasst.
  7. Verfahren nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass die Zusammensetzung p-Hydroxyacetanilid und L-Methionin oder ein physiologisch verträgliches Salz davon umfasst.
  8. Festes, nicht-granuliertes partikuläres Gemisch, das zur Verwendung in der Herstellung eines geformten pharmazeutischen Produkts durch direkte Komprimierung ohne Verwendung eines Nassverfahrensschritts geeignet ist, umfassend p-Hydroxyacetanilid und L-Cystein oder eine Verbindung, die dazu in vivo umgewandelt wird, dadurch gekennzeichnet, dass das L-Cystein oder dessen Vorstufe im wesentlichen eine Partikelgröße von weniger als 1000 µm aufweist und mit 10 bis 50 Gew.-%, bezogen auf die Menge des p-Hydroxyacetanilids, vorliegt und das Gemisch ein Bindemittel und ein Gleitmittel enthält mit der Maßgabe, dass das Gemisch kein p-Hydroxyacetanilid in einer mit Polyvinylpyrrolidon beschichteten Form, in welcher das Polyvinylpyrrolidon mit 2 bis 8 Gew.-% der Zusammensetzung vorliegt, enthält.
  9. Gemisch nach Anspruch 8, dadurch gekennzeichnet, dass es eine Menge an Wasser enthält, die im Bereich von 0,5 bis 2,5 Gew.-% des Gesamtgemischs liegt.
  10. Direkt komprimierte, geformte pharmazeutische Zusammensetzung, umfassend ein komprimiertes, nicht-granuliertes Feststoffgemisch aus p-Hydroxyacetanilid und L-Cystein oder einer Verbindung, die dazu in vivo umgewandelt wird, wie in Anspruch 8 oder Anspruch 9 definiert, zusammen mit einem physiologisch verträglichen festen Träger mit der Maßgabe, dass die Zusammensetzung kein p-Hydroxyacetanilid in einer mit Polyvinylpyrrolidon beschichteten Form, in welcher das Polyvinylpyrrolidon mit 2 bis 8 Gew.-% der Zusammensetzung vorliegt, enthält.
  11. Pharmazeutische Zusammensetzung, umfassend ein wie im Anspruch 8 definiertes Feststoffgemisch aus p-Hydroxyacetanilid und L-Cystein oder einer Verbindung die dazu in vivo umgewandelt wird.
  12. Gemisch oder Zusammensetzung nach einem der Ansprüche 8 bis 11, dadurch gekennzeichnet, dass das Bindemittel Polyvinylpyrrolidon ist.
  13. Gemisch oder Zusammensetzung nach einem der Ansprüche 8 bis 12, das/die eine Menge an Wasser enthält, die im Bereich von 0,5 bis 2,5 Gew.-% des Gesamtgemischs bzw. der Gesamtzusammensetzung liegt.
  14. Gemisch oder Zusammensetzung nach einem der Ansprüche 8 bis 13, das/die p-Hydroxyacetanilid und DL-Methionin oder ein physiologisch verträgliches Salz davon umfasst.
  15. Gemisch oder Zusammensetzung nach einem der Ansprüche 8 bis 14, das/die p-Hydroxyacetanilid und L-Methionin oder ein physiologisch verträgliches Salz davon umfasst.
  16. Pharmazeutische Zusammensetzung nach einem der Ansprüche 8 bis 15 in Tablettenform.
  17. Verwendung eines nicht-granulären Feststoffgemischs nach einem der Ansprüche 8 bis 15 zur Herstellung einer pharmazeutischen Zusammensetzung.
  18. Verwendung eines nicht-granulären Feststoffgemischs nach einem der Ansprüche 8 bis 15 zur Herstellung eines Medikaments zur Verwendung als Analgetikum oder Antipyretikum.
EP02002974A 1993-03-12 1994-03-08 Pharmazeutische Zusammensetzungen, die Paracetamol und L-Cystein oder eine Vorstufe davon enthalten Expired - Lifetime EP1210939B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939305058A GB9305058D0 (en) 1993-03-12 1993-03-12 Pharmaceutical compositions
GB9305058 1993-03-12
EP94908449A EP0689434B1 (de) 1993-03-12 1994-03-08 Pharmazeutische zusammensetzungen, die paracetamol und l-cystein oder einen vorlaeufer davon enthalten

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP94908449A Division EP0689434B1 (de) 1993-03-12 1994-03-08 Pharmazeutische zusammensetzungen, die paracetamol und l-cystein oder einen vorlaeufer davon enthalten

Publications (3)

Publication Number Publication Date
EP1210939A2 EP1210939A2 (de) 2002-06-05
EP1210939A3 EP1210939A3 (de) 2002-08-07
EP1210939B1 true EP1210939B1 (de) 2006-01-04

Family

ID=10731916

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02002974A Expired - Lifetime EP1210939B1 (de) 1993-03-12 1994-03-08 Pharmazeutische Zusammensetzungen, die Paracetamol und L-Cystein oder eine Vorstufe davon enthalten
EP94908449A Expired - Lifetime EP0689434B1 (de) 1993-03-12 1994-03-08 Pharmazeutische zusammensetzungen, die paracetamol und l-cystein oder einen vorlaeufer davon enthalten

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP94908449A Expired - Lifetime EP0689434B1 (de) 1993-03-12 1994-03-08 Pharmazeutische zusammensetzungen, die paracetamol und l-cystein oder einen vorlaeufer davon enthalten

Country Status (20)

Country Link
US (2) US5716991A (de)
EP (2) EP1210939B1 (de)
JP (1) JPH08507305A (de)
KR (1) KR960700701A (de)
CN (1) CN1118989A (de)
AT (2) ATE314842T1 (de)
AU (1) AU674934B2 (de)
BR (1) BR9406227A (de)
CA (1) CA2157921C (de)
DE (2) DE69431151T2 (de)
DK (1) DK0689434T3 (de)
ES (2) ES2176238T3 (de)
GB (2) GB9305058D0 (de)
IL (1) IL108937A (de)
NO (1) NO318493B1 (de)
NZ (1) NZ262168A (de)
PT (1) PT689434E (de)
SG (1) SG48344A1 (de)
WO (1) WO1994020086A1 (de)
ZA (1) ZA941674B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5882298A (en) * 1997-01-29 1998-08-18 Chong Kun Dang Corporation New analgesic composition
WO2001068069A2 (en) * 2000-03-15 2001-09-20 King's College London Pharmaceutical composition comprising paracetamol
KR100379155B1 (ko) * 2000-07-18 2003-04-08 삼진제약주식회사 새로운 진통제 조성물
US6623754B2 (en) 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
US20080188439A1 (en) * 2006-10-26 2008-08-07 Salhanick Steven D Directed metabolism of compounds by glucuronidation and sulfonation donors to decrease toxicity
ITMI20080187A1 (it) * 2008-02-07 2009-08-08 Velleja Res Srl Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo
JP2012533559A (ja) * 2009-07-15 2012-12-27 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アセトアミノフェンの治療効果を改善するためのｎ−アセチルシステイン組成物および方法
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200039A (en) * 1962-05-28 1965-08-10 Pfizer & Co C Non-granulated tablets with 20% sorbitol in a particle size of from about 100mu to about 2000mu
GB1287431A (en) * 1969-04-16 1972-08-31 Aspro Nicholas Ltd Improvements in pharmaceutical formulations
GB1390032A (en) * 1971-08-27 1975-04-09 Sterling Winthrop Group Ltd Pharmaceutical compositions
GB1410909A (en) * 1971-10-26 1975-10-22 Sterling Winthrop Group Ltd Pharmaceutical compositions
GB1463505A (en) * 1973-11-21 1977-02-02 Nat Res Dev Pharmaceutical compositions
GB1583602A (en) * 1977-05-26 1981-01-28 Sterwin Ag N-acetyl-para-aminophenyl-n'-acetyl-amino-thioalkanoic acid ester derivatives
EP0040472B1 (de) * 1980-05-20 1986-01-29 Mallinckrodt, Inc. (a Delaware corporation) Trockenpulverisierte N-Acetyl-p-aminophenol-Zusammensetzungen und Verfahren zu deren Herstellung
US4439453A (en) * 1980-12-22 1984-03-27 Monsanto Company Directly compressible acetaminophen granulation
GR79340B (de) * 1982-07-06 1984-10-22 Sterwin Ag
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4760093A (en) * 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US5037658A (en) * 1989-09-14 1991-08-06 Hoechst-Roussel Pharmaceuticals, Inc. Direct dry compressible acetaminophen composition
DK0481294T4 (da) * 1990-10-19 2001-06-18 Spirig Ag Fast, hurtigt-opløseligt lægemiddelpræparat indeholdende N-acetylcystein
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
FR2708602B1 (fr) * 1993-08-02 1995-10-06 Oreal Procédé d'extraction des composés malodorants présents dans une formulation contenant au moins un composé comportant un groupe thiol et compositions désodorisées ainsi obtenues.
US5370878A (en) * 1993-09-30 1994-12-06 Hallmark Pharmaceuticals, Inc. Method for preparing a direct compression granulated acetaminophen composition
JPH07130367A (ja) * 1993-10-29 1995-05-19 Sony Corp リチウム二次電池用正極活物質の製造方法

Also Published As

Publication number Publication date
CA2157921C (en) 2006-07-11
SG48344A1 (en) 1998-04-17
CA2157921A1 (en) 1994-09-15
DE69434600D1 (de) 2006-03-30
CN1118989A (zh) 1996-03-20
JPH08507305A (ja) 1996-08-06
GB9305058D0 (en) 1993-04-28
EP1210939A3 (de) 2002-08-07
AU674934B2 (en) 1997-01-16
DE69431151D1 (de) 2002-09-12
ES2176238T3 (es) 2002-12-01
GB2276319B (en) 1997-01-15
PT689434E (pt) 2002-12-31
ES2254541T3 (es) 2006-06-16
IL108937A (en) 1999-10-28
DK0689434T3 (da) 2002-12-02
EP0689434A1 (de) 1996-01-03
EP1210939A2 (de) 2002-06-05
AU6148794A (en) 1994-09-26
EP0689434B1 (de) 2002-08-07
ZA941674B (en) 1995-09-11
ATE314842T1 (de) 2006-02-15
ATE221777T1 (de) 2002-08-15
KR960700701A (ko) 1996-02-24
DE69434600T2 (de) 2006-08-24
DE69431151T2 (de) 2002-12-12
WO1994020086A1 (en) 1994-09-15
NO953515D0 (no) 1995-09-07
US5716991A (en) 1998-02-10
GB2276319A (en) 1994-09-28
NZ262168A (en) 1997-05-26
IL108937A0 (en) 1994-06-24
US5852055A (en) 1998-12-22
NO953515L (no) 1995-09-07
NO318493B1 (no) 2005-03-29
BR9406227A (pt) 1995-12-12
GB9404427D0 (en) 1994-04-20

Similar Documents

Publication Publication Date Title
US6190696B1 (en) Stabilized thyroxine medications
AU676315B2 (en) Stabilized solid pharmaceutical preparation and method of producing the same
EP2702989B1 (de) Stabile pharmazeutische zusammensetzung
UA29513C2 (uk) Фармацевтична композиція, що включає (е)-3,5-дигідрокси-7-[4'-4''-фторфеніл-2'-циклопропілхінолін-3'-іл]-6- гептенову кислоту
AT9978U1 (de) Tamsulosin-hältige matrixtablette
IL95574A (en) Colstiramine preparation
US20060222703A1 (en) Pharmaceutical composition and preparation method thereof
EP1210939B1 (de) Pharmazeutische Zusammensetzungen, die Paracetamol und L-Cystein oder eine Vorstufe davon enthalten
HUE031251T2 (en) Controlled release oral dosage form containing oxycodone
IL106743A (en) Tablets with enhanced bioavailability of claudonic acid
JP2007055924A (ja) イブプロフェン及び塩酸アンブロキソール含有固形製剤
CN1173701C (zh) 含有米氮平的口内崩解组合物
RU2236231C2 (ru) Таблетка циклофосфамида с пленочным покрытием (варианты) и способ ее получения, ядро таблетки и способ его получения
TWI286072B (en) Sleeping medicine formed by coating solid
WO2010115612A2 (en) Pregabalin compositions
JP2006327943A (ja) 経時的溶出遅延を抑制したテイストマスク錠剤
EP2117534A1 (de) Pharmazeutische zusammensetzung mit atorvastatin als wirkstoff
JP2009137872A (ja) グルクロノラクトン含有経口用固形製剤
EP4230199A1 (de) Stabile beschichtete feste pharmazeutische zusammensetzung eines opioid-analgetikums und eines antiepileptikums gegen schmerzen
WO2008038155A2 (en) Controlled-release pharmaceutical tablets
Summers et al. The bioavailability, absorption characteristics and formulation of four commercially-available controlled-release theophylline products
JP2005289903A (ja) 医薬組成物
WO2007113371A1 (en) Pharmaceutical composition and preparation method thereof
CA2345638A1 (en) Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid
WO2017114597A1 (en) Pharmaceutical dosage forms comprising ((cis)-n-(4-(dimethylamino)-1,4- diphenylcyclohexyl)-n-methylcinnamamide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 689434

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

17P Request for examination filed

Effective date: 20020211

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/198 A, 7A 61K 9/20 B, 7A 61K 31/195 B, 7A 61K 31/198 J, 7A 61K 31:167 J

17Q First examination report despatched

Effective date: 20030117

AKX Designation fees paid

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SINCLAIR PHARMACEUTICALS LIMITED

AC Divisional application: reference to earlier application

Ref document number: 0689434

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060104

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060308

REF Corresponds to:

Ref document number: 69434600

Country of ref document: DE

Date of ref document: 20060330

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060404

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060605

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2254541

Country of ref document: ES

Kind code of ref document: T3

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20061005

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: ISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060405

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20091112 AND 20091118

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Ref country code: FR

Ref legal event code: CA

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: ENN PHARMACEUTICAL SERVICES LIMITED

Free format text: SINCLAIR PHARMACEUTICALS LIMITED#BOROUGH ROAD#GODALMING, SURREY GU7 2AB (GB) -TRANSFER TO- PENN PHARMACEUTICAL SERVICES LIMITED#23-24 TAFARNAUBACH#TREDEGAR, GWENT NP22 3AA (GB)

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER & CIE S.A.

BECA Be: change of holder's address

Owner name: PENN PHARMACEUTICAL SERVICES LTDOF 23-24 TAFARNAUB

Effective date: 20100324

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20100326

Year of fee payment: 17

Ref country code: ES

Payment date: 20100302

Year of fee payment: 17

Ref country code: MC

Payment date: 20100113

Year of fee payment: 17

Ref country code: LU

Payment date: 20100217

Year of fee payment: 17

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20100323

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20100325

Year of fee payment: 17

Ref country code: BE

Payment date: 20100120

Year of fee payment: 17

Ref country code: GB

Payment date: 20100222

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20100415

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20100204

Year of fee payment: 17

BERE Be: lapsed

Owner name: PENN PHARMACEUTICAL SERVICES LTD

Effective date: 20110331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110308

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20111130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20111001

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69434600

Country of ref document: DE

Effective date: 20111001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110308

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110308

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20120423

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110309

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110308